Pub Date : 2025-07-01Epub Date: 2023-06-08DOI: 10.23822/EurAnnACI.1764-1489.301
M Rodrigues, F de Castro Mendes, I Paciência, R Barros, P Padrão, J Cavaleiro Rufo, D Silva, L Delgado, A Moreira, P Moreira
Summary: Background. Asthma is a major public health problem, with increasing prevalence in most countries, particularly among children. Poor dietary quality is also increasing in children, and evidence of the overall quality of children's food patterns effects on asthma is scarce. Methods. This cross-sectional analysis (660 children: 49.1% females, aged 7-12years) evaluated the association between diet quality and asthma (n = 56) and airway inflammation among school-aged children according to body mass index (BMI). Diet quality was assessed through the Healthy Eating Index (HEI)-2015, and categorized by tertiles. Higher scores represent a healthier diet. A questionnaire was used to enquire about self-reported medical diagnosis of asthma and asthma under medication. Lung function and airway reversibility were measured, and airway inflammation assessed measuring exhaled fractional nitric oxide (eNO). Two categories of BMI were considered: non-overweight/obese (p less than 85th), (n = 491), and overweight/obese (p ≥ than 85th), (n = 169). The associations between diet quality and asthma and airway inflammation were estimated using logistic regression models. Results. Non-overweight/obese children in 2nd tertile of HEI-2015 score had decreased odds of having eNO ≥ 35ppb (OR 0.43, 95%CI 0.19-0.98), medical diagnosis of asthma (OR 0.18; 95%CI 0.04-0.84), and asthma treatment (OR 0.12; 95%CI 0.01-0.95), compared to children in the 1st tertile. Conclusions. Our findings suggest that a higher diet quality associates with lower levels of airway inflammation and reduced prevalence of asthma among non-overweight/obese school-aged children.
{"title":"Diet quality, asthma and airway inflammation in school-aged children.","authors":"M Rodrigues, F de Castro Mendes, I Paciência, R Barros, P Padrão, J Cavaleiro Rufo, D Silva, L Delgado, A Moreira, P Moreira","doi":"10.23822/EurAnnACI.1764-1489.301","DOIUrl":"10.23822/EurAnnACI.1764-1489.301","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Asthma is a major public health problem, with increasing prevalence in most countries, particularly among children. Poor dietary quality is also increasing in children, and evidence of the overall quality of children's food patterns effects on asthma is scarce. <b>Methods.</b> This cross-sectional analysis (660 children: 49.1% females, aged 7-12years) evaluated the association between diet quality and asthma (n = 56) and airway inflammation among school-aged children according to body mass index (BMI). Diet quality was assessed through the Healthy Eating Index (HEI)-2015, and categorized by tertiles. Higher scores represent a healthier diet. A questionnaire was used to enquire about self-reported medical diagnosis of asthma and asthma under medication. Lung function and airway reversibility were measured, and airway inflammation assessed measuring exhaled fractional nitric oxide (eNO). Two categories of BMI were considered: non-overweight/obese (p less than 85<sup>th</sup>), (n = 491), and overweight/obese (p ≥ than 85<sup>th</sup>), (n = 169). The associations between diet quality and asthma and airway inflammation were estimated using logistic regression models. <b>Results.</b> Non-overweight/obese children in 2<sup>nd</sup> tertile of HEI-2015 score had decreased odds of having eNO ≥ 35ppb (OR 0.43, 95%CI 0.19-0.98), medical diagnosis of asthma (OR 0.18; 95%CI 0.04-0.84), and asthma treatment (OR 0.12; 95%CI 0.01-0.95), compared to children in the 1<sup>st</sup> tertile. <b>Conclusions.</b> Our findings suggest that a higher diet quality associates with lower levels of airway inflammation and reduced prevalence of asthma among non-overweight/obese school-aged children.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"163-175"},"PeriodicalIF":2.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9590477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-12DOI: 10.23822/EurAnnACI.1764-1489.402
D Gargano, L Franceschini, R Polillo, C M Rossi, D Bignardi, D Villalta, F Buzzulini, G Cortellini, E Pinter, M B Bilò, A Farsi
Summary: Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the esophagus affecting mainly young individuals with a high burden of comorbid atopic diseases and is associated with increased morbidity. Proton pump inhibitors (PPIs) is often the first line of treatment by inducing clinical remission in 30-50% of patients. Recently new drugs, such as budesonide orodispersible tablets and a monoclonal antibody targeting interleukin-4 and 13, have been found to be effective in clinical trials and approved to treat this condition. A prompt diagnosis and correct management of these patients is of paramount importance to prevent fibrostenosis of the oesophagus and to improve the quality of life. The complex management of patients living with EoE requires the integrated cooperation of several specialists, including allergists, gastroenterologists, pathologists, dietitians, and psychologist.
{"title":"The crucial role of allergists in the clinical management and treatment of eosinophilic esophagitis.","authors":"D Gargano, L Franceschini, R Polillo, C M Rossi, D Bignardi, D Villalta, F Buzzulini, G Cortellini, E Pinter, M B Bilò, A Farsi","doi":"10.23822/EurAnnACI.1764-1489.402","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.402","url":null,"abstract":"<p><strong>Summary: </strong>Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the esophagus affecting mainly young individuals with a high burden of comorbid atopic diseases and is associated with increased morbidity. Proton pump inhibitors (PPIs) is often the first line of treatment by inducing clinical remission in 30-50% of patients. Recently new drugs, such as budesonide orodispersible tablets and a monoclonal antibody targeting interleukin-4 and 13, have been found to be effective in clinical trials and approved to treat this condition. A prompt diagnosis and correct management of these patients is of paramount importance to prevent fibrostenosis of the oesophagus and to improve the quality of life. The complex management of patients living with EoE requires the integrated cooperation of several specialists, including allergists, gastroenterologists, pathologists, dietitians, and psychologist.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-09DOI: 10.23822/EurAnnACI.1764-1489.401
M Maged Amin, R E S Abdel Monem Galal, O M Zeyada
Summary: Background. Allergy is a multifactorial disease in which variant genetic and environmental factors are involved. Pathophysiology of food allergy (FA) and its natural history are poorly understood till now. Novel biomarkers and curative treatment options are strongly required. We aimed to study the significance of serum sphingosine 1 phosphate (S1P) level in food allergy and assess its possible correlation with disease severity. Methods. Study conducted on fifty participants diagnosed to have food allergy and another fifty group matched individuals who served as a control group. Results. The mean food allergy severity score of patients was 2.64±1.06, in which nearly two thirds (70%) are moderate, 18% are mild and about 12% of them are severe. A statistically significant increase in median value of S1P was found in patients with food allergies when compared to the control group. The best S1P cut-off level for the prediction of food allergy was (122.35 ng/L), with a sensitivity of 97.9% and a specificity of 95.7%, with a (97%) accuracy. Regarding Spearman's rho correlation analysis, a positive significant correlation was found between serum S1P level and Food allergy severity score. Conclusions. Sphingosine 1 phosphate (S1P) serum level can be a diagnostic marker for food allergy and its modulation could be a modality treatment for food allergies.
{"title":"Altered serum sphingosine 1 phosphate level in food allergy and its association with disease severity.","authors":"M Maged Amin, R E S Abdel Monem Galal, O M Zeyada","doi":"10.23822/EurAnnACI.1764-1489.401","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.401","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Allergy is a multifactorial disease in which variant genetic and environmental factors are involved. Pathophysiology of food allergy (FA) and its natural history are poorly understood till now. Novel biomarkers and curative treatment options are strongly required. We aimed to study the significance of serum sphingosine 1 phosphate (S1P) level in food allergy and assess its possible correlation with disease severity. <b>Methods.</b> Study conducted on fifty participants diagnosed to have food allergy and another fifty group matched individuals who served as a control group. <b>Results.</b> The mean food allergy severity score of patients was 2.64±1.06, in which nearly two thirds (70%) are moderate, 18% are mild and about 12% of them are severe. A statistically significant increase in median value of S1P was found in patients with food allergies when compared to the control group. The best S1P cut-off level for the prediction of food allergy was (122.35 ng/L), with a sensitivity of 97.9% and a specificity of 95.7%, with a (97%) accuracy. Regarding Spearman's rho correlation analysis, a positive significant correlation was found between serum S1P level and Food allergy severity score. <b>Conclusions.</b> Sphingosine 1 phosphate (S1P) serum level can be a diagnostic marker for food allergy and its modulation could be a modality treatment for food allergies.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01Epub Date: 2023-08-02DOI: 10.23822/EurAnnACI.1764-1489.309
G Famularo, F Casorati
{"title":"Probable apixaban-induced purpura.","authors":"G Famularo, F Casorati","doi":"10.23822/EurAnnACI.1764-1489.309","DOIUrl":"10.23822/EurAnnACI.1764-1489.309","url":null,"abstract":"","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"143-144"},"PeriodicalIF":2.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9911363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01Epub Date: 2024-06-24DOI: 10.23822/EurAnnACI.1764-1489.348
A M Durmaz, Ö Özdemir
Summary: Background. Pediatric cutaneous mastocytosis patients diagnosed and followed up by our specialist were enrolled in this study, and clinical and laboratory evaluations were retrospectively analyzed from patients' archived files. Methods. Patients, who applied to the Division of Pediatric Allergy And Immunology Unit of a University Training and Research Hospital between 01.01.2010 and 28.04.2021, were enrolled in this study. Results. Of the 33 patients included in the study, 11 (33.3%) were female and 22 (67.7%) were male. The median age of onset of the patient's complaints was 7 (0-60) months. The median age at diagnosis was 11 (2-64) months. Their complaints' median regression age was 54 (6-192) months. Resistant clinical findings were followed in 13 (39.4%) patients. Itching, redness, gastrointestinal symptoms, and maculopapular eruption were the most common complaints. The rashes were mostly polymorphic and larger than 1 cm. Heat was the most common trigger. Darier's sign was positive in 97% of the patients. Antihistamines were the most commonly used drug for prophylaxis and treatment. The autoinjector prescription rate was 24.2%. Conclusions. Quality of life was mildly affected in 48,5% of the patients based on the CDLQI scores. Thus, patients should be followed up through adolescence for the development of systemic signs and symptoms.
{"title":"Clinical spectrum of patients diagnosed with childhood mastocytosis: a retrospective single center experience.","authors":"A M Durmaz, Ö Özdemir","doi":"10.23822/EurAnnACI.1764-1489.348","DOIUrl":"10.23822/EurAnnACI.1764-1489.348","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Pediatric cutaneous mastocytosis patients diagnosed and followed up by our specialist were enrolled in this study, and clinical and laboratory evaluations were retrospectively analyzed from patients' archived files. <b>Methods.</b> Patients, who applied to the Division of Pediatric Allergy And Immunology Unit of a University Training and Research Hospital between 01.01.2010 and 28.04.2021, were enrolled in this study. <b>Results.</b> Of the 33 patients included in the study, 11 (33.3%) were female and 22 (67.7%) were male. The median age of onset of the patient's complaints was 7 (0-60) months. The median age at diagnosis was 11 (2-64) months. Their complaints' median regression age was 54 (6-192) months. Resistant clinical findings were followed in 13 (39.4%) patients. Itching, redness, gastrointestinal symptoms, and maculopapular eruption were the most common complaints. The rashes were mostly polymorphic and larger than 1 cm. Heat was the most common trigger. Darier's sign was positive in 97% of the patients. Antihistamines were the most commonly used drug for prophylaxis and treatment. The autoinjector prescription rate was 24.2%. <b>Conclusions.</b> Quality of life was mildly affected in 48,5% of the patients based on the CDLQI scores. Thus, patients should be followed up through adolescence for the development of systemic signs and symptoms.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"120-127"},"PeriodicalIF":2.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01Epub Date: 2023-09-15DOI: 10.23822/EurAnnACI.1764-1489.314
E Scala, D Abeni, V Villella, D Villalta, L Cecchi, V Pravettoni, M Giani, E Caprini, R Asero
Summary: Background. Lipid transfer proteins (LTP) allergy is often a challenge for clinicians. We evaluated a multiplex diagnostic approach with diverse cofactors to stratify LTP syndrome risk. Methods. Of the 1,831 participants screened with 'Allergy Explorer-ALEX-2', 426 had reactions to at least one LTP. Data was gathered and recorded via an electronic database. Results. Reactivity to peach Pru p 3 was found in 77% of individuals with LTP allergy. Higher levels of specific IgE and concurrent sensitization to more than 5 molecules (50% of all LTP-sensitised participants, 62% of symptomatic cases) were significantly associated with an increased risk of severe reactions (p = 0.001). Several cofactors, either alone or in combination, also influenced patients' clinical outcomes. Some cofactors increased the risk of severe reactions, such as mono reactivity to LTP in 44.6% of cases (p = 0.001), Food-Dependent Exercise-Induced Anaphylaxis (FDEIA) in 10.8% of patients (p = 0.001), and Food-dependent NSAID-induced hypersensitivity (FDNIH) in 11.5% (p = 0.005). On the other hand, reactivity to PR10 (24.2%; p = 0.001), profilin hypersensitivity (10.3%; p = 0.001), and/or atopic dermatitis (16.7%; p = 0.001) had a mitigating effect on symptom severity. Conclusions. Clinical severity of LTP syndrome is associated with an expanded IgE repertoire in terms of the number of LTP components recognized and increased IgE levels in individual molecules. Ara h 9, Cor a 8, and Mal d 3 showed the strongest association with clinical severity. In addition, several cofactors may either exacerbate (FDEIA, FDHIH, and LTP monoreactivity) or ameliorate (atopic dermatitis and co-sensitization to profilin and/or PR10) individual patient outcomes. These factors may be utilized for the daily clinical management of LTP syndrome.
摘要:背景。脂质转移蛋白(LTP)过敏通常是临床医生面临的挑战。我们评估了一种具有多种辅助因素的多重诊断方法来对LTP综合征的风险进行分层。方法。在1831名接受“过敏探索者- alex2”筛查的参与者中,426人对至少一种LTP有反应。数据是通过电子数据库收集和记录的。结果。77%的LTP过敏患者对桃子Pru p3有反应。较高水平的特异性IgE和同时致敏超过5个分子(50%的ltp致敏参与者,62%的症状病例)与严重反应的风险增加显著相关(p = 0.001)。几个辅助因素,无论是单独的还是联合的,也会影响患者的临床结果。一些辅助因素增加了严重反应的风险,例如44.6%的病例(p = 0.001)对LTP的单反应性,10.8%的患者(p = 0.001)食物依赖性运动诱导的过敏反应(FDEIA), 11.5%的患者(p = 0.005)食物依赖性非甾体抗炎药诱导的超敏反应(FDNIH)。另一方面,对PR10的反应性为24.2%;P = 0.001), profilin过敏(10.3%;P = 0.001),和/或特应性皮炎(16.7%;P = 0.001)对症状严重程度有缓解作用。结论。LTP综合征的临床严重程度与可识别的LTP成分数量和单个分子中IgE水平的增加有关。Ara h 9、Cor a 8和Mal d 3与临床严重程度的相关性最强。此外,一些辅助因素可能加剧(FDEIA, fdhh和LTP单反应性)或改善(特应性皮炎和对profilin和/或PR10的共同敏感)个体患者的结果。这些因素可用于LTP综合征的日常临床管理。
{"title":"Clinical severity of LTP syndrome is associated with an expanded IgE repertoire, FDEIA, FDNIH, and LTP mono reactivity.","authors":"E Scala, D Abeni, V Villella, D Villalta, L Cecchi, V Pravettoni, M Giani, E Caprini, R Asero","doi":"10.23822/EurAnnACI.1764-1489.314","DOIUrl":"10.23822/EurAnnACI.1764-1489.314","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Lipid transfer proteins (LTP) allergy is often a challenge for clinicians. We evaluated a multiplex diagnostic approach with diverse cofactors to stratify LTP syndrome risk. <b>Methods.</b> Of the 1,831 participants screened with 'Allergy Explorer-ALEX-2', 426 had reactions to at least one LTP. Data was gathered and recorded via an electronic database. <b>Results.</b> Reactivity to peach Pru p 3 was found in 77% of individuals with LTP allergy. Higher levels of specific IgE and concurrent sensitization to more than 5 molecules (50% of all LTP-sensitised participants, 62% of symptomatic cases) were significantly associated with an increased risk of severe reactions (p = 0.001). Several cofactors, either alone or in combination, also influenced patients' clinical outcomes. Some cofactors increased the risk of severe reactions, such as mono reactivity to LTP in 44.6% of cases (p = 0.001), Food-Dependent Exercise-Induced Anaphylaxis (FDEIA) in 10.8% of patients (p = 0.001), and Food-dependent NSAID-induced hypersensitivity (FDNIH) in 11.5% (p = 0.005). On the other hand, reactivity to PR10 (24.2%; p = 0.001), profilin hypersensitivity (10.3%; p = 0.001), and/or atopic dermatitis (16.7%; p = 0.001) had a mitigating effect on symptom severity. <b>Conclusions.</b> Clinical severity of LTP syndrome is associated with an expanded IgE repertoire in terms of the number of LTP components recognized and increased IgE levels in individual molecules. Ara h 9, Cor a 8, and Mal d 3 showed the strongest association with clinical severity. In addition, several cofactors may either exacerbate (FDEIA, FDHIH, and LTP monoreactivity) or ameliorate (atopic dermatitis and co-sensitization to profilin and/or PR10) individual patient outcomes. These factors may be utilized for the daily clinical management of LTP syndrome.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"128-139"},"PeriodicalIF":2.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10242276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01Epub Date: 2023-07-28DOI: 10.23822/EurAnnACI.1764-1489.308
R Brás, R Limão, E Pedro, A Lopes
{"title":"Pruritus burden assessment in severe atopic dermatitis patients under dupilumab: response predictor?","authors":"R Brás, R Limão, E Pedro, A Lopes","doi":"10.23822/EurAnnACI.1764-1489.308","DOIUrl":"10.23822/EurAnnACI.1764-1489.308","url":null,"abstract":"","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"140-142"},"PeriodicalIF":2.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9883828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01Epub Date: 2024-03-14DOI: 10.23822/EurAnnACI.1764-1489.337
A Palladino, F Villani, E Pinter, M Visentini, R Asero
Summary: Background. Chronic spontaneous urticaria (CSU), characterized by recurrent itchy wheals and angioedema for > 6 weeks, is a quite common disease that may heavily impair the quality of life. Omalizumab, an anti-IgE mAb, has much improved the management of CSU but patients' response to the drug may vary and predictive markers are still largely missing. We investigated the predictive value of the autologous serum skin test (ASST) on omalizumab response. Methods. 15 patients with severe CSU eligible for omalizumab treatment were prospectively studied submitting them to ASST and to complete blood count, D-dimer, anti-thyroid peroxidase antibodies, and total IgE measurement before the start of the treatment. Results. 14/15 (93%) responded brilliantly to omalizumab at 3 months assessment. 7 responded in less than 1 month ("early responders") and 7 only after multiple administrations ("late responders"). Of 9 patients scoring positive on ASST, 7 (78%) were late, and 2 (22%) early responders to omalizumab (p = 0.021). Of 6 patients scoring negative on ASST, 5 were early omalizumab responders and 1 did not respond. The PPV and NPV of the ASST for a "late" response to omalizumab were 78% and 100%, respectively. Total IgE were significantly higher in early responders. Conclusions. Although larger prospective studies are needed to confirm these results, this study confirms previous retrospective investigations that the positive ASST appears to predict a slow response to omalizumab in CSU patients.
{"title":"The autologous serum skin test predicts the response to anti-IgE treatment in chronic spontaneous urticaria patients: a prospective study.","authors":"A Palladino, F Villani, E Pinter, M Visentini, R Asero","doi":"10.23822/EurAnnACI.1764-1489.337","DOIUrl":"10.23822/EurAnnACI.1764-1489.337","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Chronic spontaneous urticaria (CSU), characterized by recurrent itchy wheals and angioedema for > 6 weeks, is a quite common disease that may heavily impair the quality of life. Omalizumab, an anti-IgE mAb, has much improved the management of CSU but patients' response to the drug may vary and predictive markers are still largely missing. We investigated the predictive value of the autologous serum skin test (ASST) on omalizumab response. <b>Methods.</b> 15 patients with severe CSU eligible for omalizumab treatment were prospectively studied submitting them to ASST and to complete blood count, D-dimer, anti-thyroid peroxidase antibodies, and total IgE measurement before the start of the treatment. <b>Results.</b> 14/15 (93%) responded brilliantly to omalizumab at 3 months assessment. 7 responded in less than 1 month (\"early responders\") and 7 only after multiple administrations (\"late responders\"). Of 9 patients scoring positive on ASST, 7 (78%) were late, and 2 (22%) early responders to omalizumab (p = 0.021). Of 6 patients scoring negative on ASST, 5 were early omalizumab responders and 1 did not respond. The PPV and NPV of the ASST for a \"late\" response to omalizumab were 78% and 100%, respectively. Total IgE were significantly higher in early responders. <b>Conclusions.</b> Although larger prospective studies are needed to confirm these results, this study confirms previous retrospective investigations that the positive ASST appears to predict a slow response to omalizumab in CSU patients.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"115-119"},"PeriodicalIF":2.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140119169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01Epub Date: 2024-02-20DOI: 10.23822/EurAnnACI.1764-1489.331
J Sánchez, L Álvarez, S Diez, J Miquel-Miquel, M Velásquez
Summary: Background. Patch testing (PT) is used to identify substances that cause allergic contact dermatitis (ACD). However, the clinical effects of allergen restrictions following PT have not been thoroughly investigated. This study aims to assess the diagnostic accuracy of PT in patients suspected of having ACD. Methods. Prospective study. PT were performed in patients with clinical diagnosis of ACD. Patients with a positive PT (case group) had a strict restriction of the suspected substance for one month. In patients with negative patch testing (control group), allergen restriction was based in clinical history. Clinical reduction (CR) of at least 50% in disease activity (CR50%) after one month of allergen restriction was considered clinically relevant. Total control was defined as clinical reduction of at least 90% (CR90%). Results. From 400 patients, 66.2% had a positive PT. The sensitivity of PT to identify CR50% was 84%, specificity 47%, PPV 53%, and NPV 81%. Only 10.5% of patients achieved CR90%. Conclusions. The PT had moderate diagnostic accuracy. It could be useful as a screening, but a positive result should be confirmed with controlled allergen restriction. The low number of patients who achieved a 90% CR invites to reconsider the allergens included in PT and the mechanistic processes of the disease.
{"title":"Diagnostic accuracy of patch testing based on clinical response to contact allergen restrictions in allergic contact dermatitis.","authors":"J Sánchez, L Álvarez, S Diez, J Miquel-Miquel, M Velásquez","doi":"10.23822/EurAnnACI.1764-1489.331","DOIUrl":"10.23822/EurAnnACI.1764-1489.331","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Patch testing (PT) is used to identify substances that cause allergic contact dermatitis (ACD). However, the clinical effects of allergen restrictions following PT have not been thoroughly investigated. This study aims to assess the diagnostic accuracy of PT in patients suspected of having ACD. <b>Methods.</b> Prospective study. PT were performed in patients with clinical diagnosis of ACD. Patients with a positive PT (case group) had a strict restriction of the suspected substance for one month. In patients with negative patch testing (control group), allergen restriction was based in clinical history. Clinical reduction (CR) of at least 50% in disease activity (CR50%) after one month of allergen restriction was considered clinically relevant. Total control was defined as clinical reduction of at least 90% (CR90%). <b>Results.</b> From 400 patients, 66.2% had a positive PT. The sensitivity of PT to identify CR50% was 84%, specificity 47%, PPV 53%, and NPV 81%. Only 10.5% of patients achieved CR90%. <b>Conclusions.</b> The PT had moderate diagnostic accuracy. It could be useful as a screening, but a positive result should be confirmed with controlled allergen restriction. The low number of patients who achieved a 90% CR invites to reconsider the allergens included in PT and the mechanistic processes of the disease.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"107-114"},"PeriodicalIF":2.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139905331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01Epub Date: 2024-11-07DOI: 10.23822/EurAnnACI.1764-1489.372
G Liccardi, M Martini, M B Bilò, L Cecchi, M Milanese, A Musarra, E Puxeddu, P Rogliani
Summary: The aim of this contribution was to highlight the "favorable" and "unfavorable" roles of domestic and non-domestic animals on airway sensitization processes and on the type/severity of the clinical symptoms induced by their exposure. We performed a literature research in MEDLINE for allergic manifestations and animals. Pets can be "allergy friends" through mechanisms related to hygiene hypothesis and translational aspects, the dual role of IgG4 antibodies for pets, and their promising role as healthcare service animals (dogs). On the contrary, animals can be "allergy enemies" when inducing allergic sensitization and respiratory symptoms (sometimes leading to severe reactions), and also due to cross reactivity with other pets allergens, indirect exposure and ubiquity of their allergens, cross reactivity between Can f 5 and human prostate-specific antigen (PSA). Moreover, in some cases they can trigger anaphylaxis, induce occupational asthma, and act as pests. Finally, we must outline the modest efficacy of allergen immunotherapy (AIT) for their allergens. From a strictly allergological perspective, it is evident that the "negative" aspects resulting from exposure to domestic / non-domestic animals outweigh the "positive" aspects. As a consequence, it is up to humans to seek new ways to balance the pros and cons by exploring research areas that can allow the best possible coexistence with subjects at risk of allergy with domestic and non-domestic animals.
{"title":"A narrative review on allergy and exposure to domestic and non-domestic animals: favorable and unfavorable effects.","authors":"G Liccardi, M Martini, M B Bilò, L Cecchi, M Milanese, A Musarra, E Puxeddu, P Rogliani","doi":"10.23822/EurAnnACI.1764-1489.372","DOIUrl":"10.23822/EurAnnACI.1764-1489.372","url":null,"abstract":"<p><strong>Summary: </strong>The aim of this contribution was to highlight the \"favorable\" and \"unfavorable\" roles of domestic and non-domestic animals on airway sensitization processes and on the type/severity of the clinical symptoms induced by their exposure. We performed a literature research in MEDLINE for allergic manifestations and animals. Pets can be \"allergy friends\" through mechanisms related to hygiene hypothesis and translational aspects, the dual role of IgG4 antibodies for pets, and their promising role as healthcare service animals (dogs). On the contrary, animals can be \"allergy enemies\" when inducing allergic sensitization and respiratory symptoms (sometimes leading to severe reactions), and also due to cross reactivity with other pets allergens, indirect exposure and ubiquity of their allergens, cross reactivity between Can f 5 and human prostate-specific antigen (PSA). Moreover, in some cases they can trigger anaphylaxis, induce occupational asthma, and act as pests. Finally, we must outline the modest efficacy of allergen immunotherapy (AIT) for their allergens. From a strictly allergological perspective, it is evident that the \"negative\" aspects resulting from exposure to domestic / non-domestic animals outweigh the \"positive\" aspects. As a consequence, it is up to humans to seek new ways to balance the pros and cons by exploring research areas that can allow the best possible coexistence with subjects at risk of allergy with domestic and non-domestic animals.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"99-106"},"PeriodicalIF":2.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142602131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}